FDA Approved: XOFIGO — Original Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved XOFIGO (radium-223 dichloride) as the original application for treating metastatic castration-resistant prostate cancer with symptomatic bone metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

ORIG AP for XOFIGO (RADIUM RA 223 DICHLORIDE)